Evidence map›Paper›PMID 35166864›Full record

GuidelineDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen2022

[Living guideline on ulcerative colitis].

Torsten Kucharzik

Abstract readReviewPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Torsten KucharzikKlinik für Allgemeine Innere Medizin und Gastroenterologie, Klinikum Lüneburg, Bögelstr. 1, 21339, Lüneburg, Deutschland. torsten.kucharzik@klinikum-lueneburg.de.
Klinikum Lüneburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment spectrum for ulcerative colitis has greatly increased in recent years. Mesalazine is still the standard drug treatment for uncomplicated ulcerative colitis in various forms of administration. Glucocorticoids are highly effective in the acute treatment of ulcerative colitis but should only be used on a short-term basis due to the pronounced side effects. For forms with a complicated course of ulcerative colitis, immunosuppressive and immunomodulating substances, such as azothioprine as well as various biologicals, Janus kinase inhibitors (JAKi), sphingosine-1-phosphate receptor agonists (S1PR agonists) and calcineurin inhibitors are available after failure of conventional treatment. A proctocolectomy should be considered in cases of a treatment-refractive course or with detection of carcinomas and high-grade epithelial dysplasia.

Indexed as

Colitis, UlcerativeProctocolectomy, RestorativeGlucocorticoidsHumansImmunosuppressive AgentsMesalamineGlucocorticoidsImmunosuppressive AgentsMesalamineBiologicalsGlucocorticoidsMesalizineProctocolectomySide effects

Identifiers

PMID35166864
OpenAlexW4213174978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.